148 related articles for article (PubMed ID: 30865522)
1. PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE.
Al-Kawas F; Anderson MA; Enns R; Wilson TH; Johnson S; Mallory JM
Endocr Pract; 2019 Jul; 25(7):698-716. PubMed ID: 30865522
[No Abstract] [Full Text] [Related]
2. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
Ahrén B; Carr MC; Murphy K; Perkins C; Rendell M; Mallory J; Wilson T; Johnson S
Diabetes Res Clin Pract; 2017 Apr; 126():230-239. PubMed ID: 28284167
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
[TBL] [Abstract][Full Text] [Related]
4. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.
Davis PN; Ndefo UA; Oliver A; Payton E
Am J Health Syst Pharm; 2015 Jul; 72(13):1097-103. PubMed ID: 26092960
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
Fisher M; Petrie MC; Ambery PD; Donaldson J; Ye J; McMurray JJ
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):697-703. PubMed ID: 26276240
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
7. Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.
Davidson JA; Jones-Leone A; Wilson TH; Nino A; Forero-Schwanhaeuser S; Reinhardt RR
Postgrad Med; 2017 Nov; 129(8):849-857. PubMed ID: 29083275
[TBL] [Abstract][Full Text] [Related]
8. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Trujillo JM; Nuffer W
Ann Pharmacother; 2014 Nov; 48(11):1494-501. PubMed ID: 25136065
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.
Brønden A; Knop FK; Christensen MB
Clin Pharmacokinet; 2017 Jul; 56(7):719-731. PubMed ID: 28050889
[TBL] [Abstract][Full Text] [Related]
10. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF; Green JB; Janmohamed S; D'Agostino RB; Granger CB; Jones NP; Leiter LA; Rosenberg AE; Sigmon KN; Somerville MC; Thorpe KM; McMurray JJV; Del Prato S;
Lancet; 2018 Oct; 392(10157):1519-1529. PubMed ID: 30291013
[TBL] [Abstract][Full Text] [Related]
11. Albiglutide for the management of type 2 diabetes.
Rendell MS
Expert Rev Endocrinol Metab; 2018 Jan; 13(1):1-8. PubMed ID: 30063441
[TBL] [Abstract][Full Text] [Related]
12. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
Hompesch M; Jones-Leone A; Carr MC; Matthews J; Zhi H; Young M; Morrow L; Reinhardt RR
Diabetes Obes Metab; 2015 Jan; 17(1):82-90. PubMed ID: 25263215
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Nauck MA; Stewart MW; Perkins C; Jones-Leone A; Yang F; Perry C; Reinhardt RR; Rendell M
Diabetologia; 2016 Feb; 59(2):266-74. PubMed ID: 26577795
[TBL] [Abstract][Full Text] [Related]
14. Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.
Okuda I; Wilson TH; Yue L; Nakajima H; Carr MC; Tsuboi M; Nino A; Seino Y
Curr Med Res Opin; 2017 Mar; 33(3):431-438. PubMed ID: 27852119
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
[TBL] [Abstract][Full Text] [Related]
16. The safety of albiglutide for the treatment of type 2 diabetes.
Rendell MS
Expert Opin Drug Saf; 2017 Sep; 16(9):1089-1097. PubMed ID: 28678550
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis.
Kamrul-Hasan ABM; Dutta D; Nagendra L; Bhattacharya S; Singla R; Kalra S
Medicine (Baltimore); 2024 Jun; 103(25):e38568. PubMed ID: 38905435
[TBL] [Abstract][Full Text] [Related]
18. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.
Seino Y; Nakajima H; Miyahara H; Kurita T; Bush MA; Yang F; Stewart MW
Curr Med Res Opin; 2009 Dec; 25(12):3049-57. PubMed ID: 19863477
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
Matthews JE; Stewart MW; De Boever EH; Dobbins RL; Hodge RJ; Walker SE; Holland MC; Bush MA;
J Clin Endocrinol Metab; 2008 Dec; 93(12):4810-7. PubMed ID: 18812476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
